Gene Therapy Manufacturing: A Dual Platform Reconciling Adherence and Suspension Approaches

Published on: 


Thursday, July 15, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST What adherence and suspension-based technologies are best for gene therapy production? In this webinar, learn about a next-generation dual platform solution for viral vector manufacturing that helps to overcome existing barriers to scaling and commercializing gene therapies.

Register Free:

Event Overview:

With clinical successes continuing to grow, investment in the gene therapy market is higher than ever. This success is prompting technology developers to seek flexible and scalable solutions to accommodate a diverse landscape of products and processes.
Traditionally, it has been hard to find a scalable solution for gene therapy processes, presenting barriers to innovation. But what if one platform was available to decouple the technology from the target scale?

This presentation, will describe the first dual platform, next-generation solution for gene therapy manufacture designed to reconcile the varying needs and constraints of the current gene therapy landscape. Attendees will learn how this platform:

  • Boosts specific cell productivity and process scalability
  • Enables flexibility in the choice of expression system and process parameters
  • Accelerates processes through to commercialization via automation and integration
  • Decreases footprint, resources, operator involvement, time and money

Key Learning Objectives:

  • How annual demand has polarized gene therapy manufacturing technologies
  • How to optimize manufacturing strategies with a dual platform approach
  • What impact a dual platform has on capacity and footprint

Who Should Attend:

  • Scientists
  • Researchers
  • Process development experts
  • Manufacturing experts
  • Cell and gene therapy experts


Tania Pereira Chilima
Chief Technology Officer
Univercells Technologies

Tania Pereira Chilima is the chief technology officer at Univercells Technologies where she focuses driving innovation to design best-in-class technologies answering the growing demand of viral vectors for gene therapies and vaccines. She also oversees the direction of the technology portfolio and is responsible for continuously identifying new technologies that could complement our portfolio as well as the application of our systems to new modalities.

Prior to this role, she was product manager for the NevoLine™ platform at Univercells, and previously worked as a post-doctorate researcher for the ULTRA grant sponsored by the Bill and Melinda Gates foundation, focused on designing manufacturing strategies for ultra-low-cost vaccine manufacture.

Tania holds an engineering doctorate from the University College London in partnership with Pall Life Sciences entitled, Decisional Tools for Enabling Successful Manufacture and Commercialization of Cell Therapy Products and is a frequent contributor to industry publications and journals.

Register Free: